Study Primary Objective
The aim of this prospective pilot study was to explore if treatment selection based on Multi-omic Profiling (MoP) provides clinical benefits superior to empiric treatment selection in progressive metastatic breast cancers (MBC).
- This study confirmed the unique role of MoP in selecting effective treatments for MBC.
- This approach provided clinical benefits for 56% of previously treated MBC patients, which met the primary objective of the study.
- This study also suggests that irinotecan may be an under-developed drug for MBC patients.
- As such, this approach merits further investigation.